Fly News Breaks for January 21, 2020
Jan 21, 2020 | 07:23 EDT
H.C. Wainwright analyst Debjit Chattopadhyay raised Mersana Therapeutics' price target to $12 from $7 and reiterates a But rating on the shares. Safety of the dolaflexin platform is being increasingly validated with the 43 mg/m dose moving to the expansion cohort, Chattopadhyay tells investors in a research note.
News For MRSN From the Last 2 Days
There are no results for your query MRSN